Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) has scheduled the announcement of its fourth quarter and full-year 2024 financial results for February 26, 2025. The company will provide a corporate update and host a conference call on the same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Participants must pre-register for the conference call to receive their individual dial-in number and unique access PIN. A listen-only webcast option will also be available, and a replay of the call will be accessible through the Investors / Events section of Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 26 febbraio 2025. L'azienda fornirà un aggiornamento aziendale e ospiterà una conferenza telefonica lo stesso giorno alle 17:00 ora orientale (14:00 ora del Pacifico).
I partecipanti devono pre-registrarsi per la conferenza telefonica per ricevere il proprio numero di accesso e il PIN unico. Sarà disponibile anche un'opzione di webcast in ascolto solo, e una registrazione della chiamata sarà accessibile attraverso la sezione Investitori / Eventi di Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 26 de febrero de 2025. La compañía proporcionará una actualización corporativa y realizará una llamada de conferencia el mismo día a las 5:00 p.m. Hora del Este (2:00 p.m. Hora del Pacífico).
Los participantes deben registrarse previamente para la llamada de conferencia para recibir su número de acceso y PIN único. También estará disponible una opción de webcast solo para escuchar, y una repetición de la llamada será accesible a través de la sección de Inversores / Eventos en Corcept.com.
Corcept Therapeutics (NASDAQ: CORT)는 2025년 2월 26일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 동부 표준시 오후 5시(태평양 표준시 오후 2시)에 기업 업데이트를 제공하고 컨퍼런스 콜을 주최할 것입니다.
참가자는 개별 전화 접속 번호와 고유한 접근 PIN을 받기 위해 컨퍼런스 콜에 사전 등록해야 합니다. 듣기 전용 웹캐스트 옵션도 제공되며, 콜의 재생은 Corcept.com의 투자자 / 이벤트 섹션을 통해 접근할 수 있습니다.
Corcept Therapeutics (NASDAQ: CORT) a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 pour le 26 février 2025. L'entreprise fournira une mise à jour de l'entreprise et animera une conférence téléphonique le même jour à 17h00, heure de l'Est (14h00, heure du Pacifique).
Les participants doivent préenregistrer pour la conférence téléphonique afin de recevoir leur numéro d'accès individuel et leur code PIN unique. Une option de webdiffusion en écoute seule sera également disponible, et un enregistrement de l'appel sera accessible via la section Investisseurs / Événements de Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 26. Februar 2025 angesetzt. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time (14:00 Uhr Pacific Time) ein Unternehmensupdate geben und eine Telefonkonferenz veranstalten.
Die Teilnehmer müssen sich im Voraus für die Telefonkonferenz registrieren, um ihre individuelle Einwahlnummer und die einzigartige Zugangs-PIN zu erhalten. Es wird auch eine nur hörbare Webcast-Option zur Verfügung stehen, und eine Wiederholung des Anrufs wird über den Bereich Investoren / Veranstaltungen auf Corcept.com zugänglich sein.
- None.
- None.
Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
Additionally, a listen-only webcast will be available by clicking here.
A replay of the call will be available on the Investors / Events tab of Corcept.com.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212285353/en/
Investor inquiries:
ir@corcept.com
Media inquiries:
communications@corcept.com
www.corcept.com
Source: Corcept Therapeutics Incorporated
FAQ
When will Corcept Therapeutics (CORT) release Q4 and full-year 2024 earnings?
What time is CORT's Q4 2024 earnings conference call?
How can investors access CORT's Q4 2024 earnings call?
Will there be a replay available for CORT's Q4 2024 earnings call?
